Minerva S.A.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Fernando Galletti de Queiroz
- Full Time Employees
- 40,000
- Sector
- Consumer Defensive
- Industry
- Agricultural Farm Products
- Address
- Avenida Antônio Manço Bernardes s/nº Barretos SP Brazil 14781-545
- IPO Date
- Aug 22, 2012
- Website
- minervafoods.com
- Similar Companies
- Business
- Minerva S.A. (MRVSY) is a leading South American producer and exporter of fresh beef, live cattle, and by-products, with operations in beef, lamb, pork, and poultry processing segments; the company slaughters cattle across 46 industrial units in Brazil, Paraguay, Argentina, Uruguay, Colombia, Chile, and Australia, operates 23 distribution centers and 18 international offices serving over 100 countries on five continents, and offers branded products including Minerva, Estancia 92, Minerva Angus, Minerva Seleção, Minerva Do Mestre, Frigomerc, Cabaña Las Lilas, Pul, and organic lines, alongside subsidiaries such as Minerva Fine Foods for processed meats, Minerva Ingredients for tallow, meat and bone meal, and bovine blood meal, Minerva Energia for electric power trading, Minerva Leather, Minerva Casings, Minerva Biodiesel, and MyCarbon for carbon credits. Founded in 1957 by the Vilela de Queiroz family and headquartered in Barretos, São Paulo, Brazil, Minerva targets global markets including China, North America, Europe, the Middle East, and Asia, with a slaughter capacity exceeding 40,000 head of cattle per day post-expansions and a focus on sustainability through carbon-neutral certifications, renewable energy seals, and supply chain traceability. In late 2024, the company completed its largest acquisition to date by purchasing 16 Marfrig assets for R$7.5 billion, adding 13 cattle and sheep slaughter and deboning plants plus a distribution center in Brazil, a plant in Argentina, and a lamb facility in Chile, boosting Brazilian slaughter capacity to 22,336 head per day across 21 plants and establishing Chile as a new market; this transformational deal, integrated by early 2025, enhanced synergies, market arbitrage, and leadership as South America's top beef exporter with the most plants approved for China. In 2023, Minerva acquired Breeders and Packers Uruguay SA (BPU Meat) for US$40 million, adding 1,200 head per day capacity in Uruguay, and expanded sheep operations in Australia via joint ventures; recent financial moves include a 2025 Q3 free cash flow of R$2.5 billion, net revenue guidance of R$50-58 billion for 2025, and progress with MyCarbon partnerships covering 145,700 hectares for carbon projects, alongside J.P. Morgan collaborations for working capital optimization supporting growth.
Minerva Launches AI Platform for Consumer Marketing with $20M from The General Partnership, 8VC, Lingotto Innovation, Topology Ventures and NBA Investments, Alongside OpenAI Collaboration
Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
Minerva S.A. (MRVSY) Q1 2026 Earnings Call Transcript
MINERVA FOODS REPORTS R$ 13.4 BILLION IN NET REVENUE IN THE FIRST QUARTER OF 2026
Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
Minerva Announces Leadership Transition
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026
Minerva S.A. (MRVSY) Q4 2025 Earnings Call Transcript
MINERVA FOODS REPORTS RECORD NET REVENUE OF R$ 54.8 BILLION IN 2025
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
Minerva Neurosciences to Participate in The Citizens Life Sciences Conference
Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors
Minerva S.A. (MRVSY) Q3 2025 Earnings Call Transcript
Minerva Foods' free cash flow reaches R$2.5 billion in the third quarter of 2025.
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved